May 12, 2021
Japan’s key reimbursement policy panel on May 12 agreed to apply a 4.3% downward price adjustment for Alexion Pharmaceuticals’ Ultomiris (ravulizumab) under the cost-effectiveness assessment (CEA) system. The Central Social Insurance Medical Council, better known as Chuikyo, approved the health...read more